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Background
European SOHO is a prospective, observational study of
antipsychotic treatment in 10 European countries.
Materials and methods
Clinical effectiveness and Qol were assessed using the
Clinical Global Impression (CGI) scale and the EQ-5D
instrument, respectively. For analysis, the 2-year period
was split into four 6-month epochs (0–6, 6–12, 12–18
and 18–24 months). Multivariate modelling was per-
formed, adjusting for baseline differences among patients.
Results
Olanzapine-treated patients had statistically higher over-
all CGI improvements during i) the first 6 months, com-
pared with risperidone (0.20; 0.14–0.26), quetiapine
(0.24; 0.15–0.33), amisulpride (0.12; 0.00–0.23), oral
(0.33; 0.25–0.41) and depot typicals (0.33; 0.24–0.42)
treated patients, and ii) second 6 months compared with
oral typicals (0.12; 0.04–0.19) treated patients. No statis-
tical separation was observed between the olanzapine and
clozapine groups.
Olanzapine-treated patients had statistically higher EQ-
5D utility improvements during the first 6 months com-
pared with risperidone (0.034; 0.015–0.053), quetiapine
(0.033; 0.010–0.061), amisulpride (0.043; 0.006–0.080),
oral (0.075; 0.050–0.100) and depot typicals (0.073;
0.045–0.102) treated patients. No statistical separation
was observed between the olanzapine and clozapine
groups.
Discussion
Olanzapine appears to have a range of modest effective-
ness and Qol advantages, appearing during the first 6
months of treatment and remaining thereafter, over other
antipsychotic medications, except clozapine.
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